Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Tuesday, September 30, 2025 1 min read
Key Takeaway: AbbVie Inc. has updated its guidance for the quarter ended September 30, 2025, reflecting the impact of acquired IPR D and milestone expenses. The guidance shows an adjusted diluted EPS range that is less favorable due to these expenses, projecting a decrease for Q3 2025 specifically. The report notes that these adjustments are consistent with the company's previously announced guidance, excluding these one-time costs. The company emphasizes that further expenses related to IPR D beyond Q3 2025 cannot be reliably forecasted.
Market Sentiment Analysis
CONCERNS & RISKS
The company's adjusted diluted EPS guidance has been negatively impacted by non-recurring expenses from acquired IPR D.
The expenses for Q3 2025 are projected to decrease EPS significantly, indicating potential financial challenges.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended September 30, 2025
Full-Year Ended December 31, 2025
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q3 2025 acquired IPR D and milestones expense
$
-
$
3.24
$
3.28
$
1,071
$
11.88
$
12.08
Q3 2025 acquired IPR D and milestones expense
2,680
(1.50)
(1.50)
2,680
(1.50)
(1.50)
Guidance including Q3 2025 acquired IPR D and milestones expense a
$
2,680
$
1.74
$
1.78
$
3,751
$
10.38
$
10.58
a The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the third quarter of 2025, as both cannot be reliably forecasted.
Frequently Asked Questions
What was the acquired IPR D expense for Q3 2025?
The acquired IPR D and milestones expense for Q3 2025 was $2,680 million.
What is the adjusted diluted EPS range for FY 2025?
The adjusted diluted EPS range for FY 2025 is $10.38 to $10.58.
How does Q3 2025 expense affect the adjusted EPS?
Including the Q3 2025 expense, the adjusted EPS is projected at $1.74 to $1.78.
Is there any forecast for expenses beyond Q3 2025?
No, the guidance excludes expenses beyond Q3 2025 as they cannot be reliably forecasted.
What was the previously announced diluted EPS guidance?
The previously announced guidance was $3.24 to $3.28 for adjusted diluted EPS.